ITI-1284 20 mg

DRUG3 trials

Sponsors

Intra-Cellular Therapies, Inc.

Conditions

Generalized Anxiety DisorderHealthy Volunteers

Phase 1

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

CompletedNCT06299410

Intra-Cellular Therapies, Inc.Healthy Volunteers

Start: 2024-04-11End: 2026-08-18Updated: 2026-09-01

Phase 2

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

RecruitingNCT06480383

Intra-Cellular Therapies, Inc.Generalized Anxiety Disorder

Start: 2024-08-05End: 2027-03-23Target: 705Updated: 2026-08-31

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

RecruitingNCT06701903

Intra-Cellular Therapies, Inc.Generalized Anxiety Disorder

Start: 2024-11-21End: 2028-07-20Target: 570Updated: 2026-08-31